Stuart Piltch Shares Developments in the Biosimilar Landscape

Biosimilar drugs, a biological product highly similar to but with no clinically meaningful difference from an existing reference product (drug), are expected to reduce drug costs by $181 billion over the next five years. They also hold the potential to offer more cost-effective treatments in high-cost drug categories by introducing competitively priced alternatives.

Given the frenzied pace of the pharmacy industry, our team of clinical pharmacists and financial experts came together to analyze the numerous factors contributing to the complex environment for Pharmacy Benefit Managers (PBMs) when developing and/or executing a biosimilar strategy. These discoveries are now available to you in our new white paper, Developments and Considerations in the Biosimilar Landscape.

In this white paper, you’ll learn about the intense focus on Humira, manufacturer market shift tactics and competition, its interchangeability status, and why there is urgency for increased transparency and alignment between PBMs and plan sponsors.

The Risk Strategies Consulting Pharmacy team is comprised of experienced clinical pharmacists and financial experts with deep industry knowledge of both PBMs and the pharmaceutical supply chain. Risk Strategies Consulting is a full-service consultancy, advocating for clear communication of financial modeling, clinical management approaches, and market shift forecasting of biosimilar strategies for plan sponsors.